Intellectual property articles from across Nature Portfolio

The predominance of manufacturing process patents asserted in litigation by originator biologics companies against would-be biosimilar entrants has resulted in a number of Congressional and administrative agency proposals that could increase scrutiny and limit enforceability.

Patients need the patent system to spur the investment necessary for the continued development of life-saving diagnostics and therapies.

Obtaining European patent protection for medical uses of known products is not a key factor limiting repurposing activity.

European Patent Office data show an increasing number of patents for new medical uses of known products.

A process for the non-arbitrary determination of obviousness based on examining actual patenting practices of large groups could improve outcomes.